Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Intermittent self-catheterisation in MS.
Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.
Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies: A Comparative Study.
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.
Biogen Idec receives negative opinion from the CHMP on Fampyra
B cells and multiple sclerosis.
Emotional Change-Associated T Cell Mobilization at the Early Stage of a Mouse Model of Multiple Sclerosis.
Interferons beta have vasoconstrictive and procoagulant effects: A woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis.
Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.
Natalizumab Use During the Third Trimester of Pregnancy.
European Commission Approves Genzyme’s Once-Daily, Oral Multiple Sclerosis Treatment Aubagio® (teriflunomide)
Genzyme Assumes Primary Responsibility for the Development and Commercialization of Alemtuzumab for Multiple Sclerosis; Acquires Bayer’s Hematologic Oncology Portfolio; First of Two Alemtuzumab MS Phase 3 Trials Completes Enrollment
Individual axons regulate the myelinating potential of single oligodendrocytes in vivo.
Urodynamic and physiologic patterns associated with the common causes of neurogenic bladder in adults.
Receptos reports third quarter 2013 financial results
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes.
Change in the clinical development program for laquinimod
The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple scl
LKB1-regulated adaptive mechanisms are essential for neuronal survival following mitochondrial dysfunction.
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
Oligodendrocyte death results in immune-mediated CNS demyelination.
Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis.
Altered serum content of brain-derived neurotrophic factor isoforms in multiple sclerosis.

Pages